대장암 발증 가능성의 판정 방법

• Main Authors: TANAKA KOJI, TOIYAMA YUJI, MITSUI AKIRA, TAKEHANA KENJI, KUSUNOKI MASATO, ARAKI TOSHIMITSU, UMEZAWA TSUTOMU
• Format: Patent
• Language: Korean
• Published: 02.05.2019
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; DIAGNOSIS; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; IDENTIFICATION; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; SURGERY; VINEGAR; WINE

본 발명은, 인간 궤양성 대장염 환자로부터 채취된 생체 시료로부터 회수된 DNA 중의 특정한 메틸화 가변 영역 중에 존재하는 1개 이상의 CpG 사이트의 메틸화율을 측정하는 측정 공정과, 측정된 메틸화율에 기초하여 산출된 메틸화 가변 영역의 평균 메틸화율과, 미리 설정된 기준값 또는 미리 설정된 다변량 판별식에 기초하여, 상기 인간 궤양성 대장염 환자의 대장암 발증의 가능성을 판정하는 판정 공정을 가지며, 상기 기준값이, 각 메틸화 가변 영역의 메틸화율에 대해 각각 설정된, 발암 궤양성 대장염 환자와 비암 궤양성 대장염 환자를 식별하기 위한 값이며, 상기 다변량 판별식이, 특정한 메틸화 가변 영역 중의 1개소 이상의 메틸화 가변 영역의 평균 메틸화율을 변수로서 포함하는, 인간 궤양성 대장염 환자의 대장암 발증 가능성을 판정하는 방법 등을 제공한다. The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.